

Press Release:

Phaeosynt successfully closes 1.7 million Euro seed financing round

Hannover, 12.02.25 – An important milestone for Phaeosynt: The biotech startup has successfully completed its seed capital increase of almost 1.7 million euros. This financing round not only provides the company with further growth capital, but also with the support of strong investors who share Phaeosynt's vision.

"We are very pleased with the confidence of our existing and new investors. This funding brings us a decisive step closer to launching hey mela, the world's first vegan pregnancy test," said Stephanie Pfeil-Coenen, CEO of Phaeosynt.

Existing and new investors focus on innovation

Not only have existing investors from the pre-seed round reaffirmed their commitment, but new investors have also joined the mission.

New aboard:

- PSD Braunschweig Verwaltungs-GmbH (100%ige Subsidiary of PSD Bank)
- **NBank Capital Beteiligungsgesellschaft mbH**
- Renditei UG
- TrueNorth Ventures UG
- Thomas Tönnemann
- Fonde Ventures
- Ulrich Gehrke

The new funds will be used specifically for production, market entry and scaling. Following successful CE certification, Phaeosynt will launch hey mela in summer 2025, offering a sustainable, innovative alternative to conventional pregnancy tests.

"We are using this funding to expand our team, invest in manufacturing and drive expansion. Our goal is to provide a reliable, ethical and sustainable option in diagnostics," Pfeil-Coenen concluded.

With this successful financing round, Phaeosynt is setting a strong example for innovation in the field of biotech diagnostics and is ready for the next phase of growth.

About Phaeosynt:

Phaeosynt is a biotech start-up based in Hanover, Germany, specializing in the sustainable production of vegan antibodies. With hey mela, the world's first vegan pregnancy test, the company combines biotechnology with sustainability and innovation..

Pressekontakt:

Lina Altmann

altmann@phaeosynt.com

www.phaeosynt.com